Barinthus Biotherapeutics (BRNS) Current Deferred Revenue (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Current Deferred Revenue came in at $318000.0 in Q1 2026, down 78.23% YoY from $1.5 million in Q1 2025, and down 77.22% on a QoQ basis from $1.4 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Current Deferred Revenue (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 6 years of Current Deferred Revenue data on file, last reported at $318000.0 in Q1 2026.
- Quarterly Current Deferred Revenue fell 78.23% year-over-year to $318000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $318000.0 (down 78.23% YoY) and the FY2025 annual result came in at $1.4 million, down 19.68% from the prior year.
- Current Deferred Revenue slipped to $318000.0 in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $2.0 million in Q3 2024 to a low of $111000.0 in Q3 2022.
- A 4-year average of $1.0 million and a median of $1.4 million in 2025 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2025 — Current Deferred Revenue soared 81.76% — and 2026, when it tumbled 78.23%.
- Tracing BRNS's Current Deferred Revenue over 4 years: stood at $111000.0 in 2022, then soared by 1465.77% to $1.7 million in 2024, then decreased by 19.68% to $1.4 million in 2025, then slumped by 77.22% to $318000.0 in 2026.
- The last three Current Deferred Revenue figures came in at $318000.0 (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Barinthus Biotherapeutics | 25.01 Mn | 25.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 335,000.00 |
| Mar 31, 2026 | 318,000.00 |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 1.53 Mn |
| Mar 31, 2025 | 1.46 Mn |
| Dec 31, 2024 | 1.74 Mn |
| Sep 30, 2024 | 2.04 Mn |
| Jun 30, 2024 | 839,000.00 |
| Mar 31, 2024 | 1.43 Mn |
| Sep 30, 2022 | 111,000.00 |
| Jun 30, 2022 | 136,000.00 |
| Mar 31, 2022 | 162,000.00 |
| Dec 31, 2021 | 182,000.00 |
| Sep 30, 2021 | 196,000.00 |
| Jun 30, 2021 | 217,000.00 |
| Mar 31, 2021 | 346,000.00 |
| Dec 31, 2020 | 245,000.00 |